更新的子宫内膜癌FIGO分期:MRI在确定新增组织病理学标准中的作用
研究纳入2018年2月至2023年12月106例子宫内膜癌患者,术前行盆腔MRI并测量肿瘤最大径、肿瘤ADC最小值及ADC肿瘤/肌层比值,与组织病理学对比。结果显示MRI指标在区分组织学亚型、分级及预测淋巴血管间隙浸润方面有统计学差异,肿瘤大小、ADC肿瘤及ADC肿瘤/肌层比值区分低级别与高级别肿瘤的AUC分别为0.842、0.781和0.747,预测LVSI的AUC分别为0.836、0.719和0.696。
要点
- 肿瘤大小、ADC肿瘤及ADC肿瘤/肌层比值在区分低级别与高级别子宫内膜癌中有统计学差异。
- 肿瘤增大、ADC肿瘤降低、ADC肿瘤/肌层比值降低及盆腔腹膜种植与LVSI显著相关。
- 肿瘤大小、ADC肿瘤及ADC肿瘤/肌层比值预测LVSI的AUC分别为0.836、0.719和0.696。
核心结论
- MRI有助于基于更新FIGO标准预测子宫内膜癌的组织学亚型、分级和LVSI,但仍需多中心研究验证。
研究设计与样本
- 研究纳入2018年2月至2023年12月共106例诊断为子宫内膜癌的患者,术前行盆腔MRI,手术遵循ESMO指南,组织病理学评估采用FIGO 2009标准;两名放射科医生独立评估MRI图像,测量肿瘤最大径、肿瘤ADC最小值(自由手绘ROI技术)及ADC肿瘤/肌层比值,并与组织病理学数据比较。
关键影像表现/征象
- 子宫内膜样腺癌与非子宫内膜样子宫内膜癌之间,腹膜种植的存在和肿瘤大小差异有统计学意义,P值分别为<0.001和0.003。
- 低级别与高级别肿瘤之间,年龄、肿瘤大小、ADC肿瘤及ADC肿瘤/肌层比值的差异有统计学意义,P值分别为<0.001、0.004、0.006和0.011。
- 肿瘤增大、ADC肿瘤降低、ADC肿瘤/肌层比值降低及盆腔腹膜种植的存在与LVSI显著相关,P值分别为<0.001、0.001、0.002和0.001。
诊断标准与关键数值
- 肿瘤大小区分低级别与高级别子宫内膜肿瘤的AUC为0.842。
- ADC肿瘤区分低级别与高级别子宫内膜肿瘤的AUC为0.781。
- ADC肿瘤/肌层比值区分低级别与高级别子宫内膜肿瘤的AUC为0.747。
- 肿瘤大小预测LVSI的AUC为0.836。
- ADC肿瘤预测LVSI的AUC为0.719;ADC肿瘤/肌层比值预测LVSI的AUC为0.696。
临床应用与阅片要点
- 作者认为MRI可基于更新FIGO标准预测组织学亚型、分级和LVSI,有助于改善子宫内膜癌的诊断和临床管理。
- 作者提出需进一步多中心研究验证这些发现并确立MRI在子宫内膜癌管理中的作用。
局限性
- 原文结论提出需进一步多中心研究验证这些发现并确立MRI在子宫内膜癌管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Endometrial cancer (EC) is among the prevalent malignancies in gynecology, showing an increasing occurrence and mortality rate. The updated 2023 FIGO staging integrates both histopathological and molecular analyses, which significantly impact the prognosis and treatment approaches. This research aims to examine the effectiveness of MRI in identifying essential histopathological tumor features, including histological subtype, grade, and lymphovascular space invasion.
METHODS: A total of 106 patients diagnosed with EC from February 2018 to December 2023 underwent preoperative pelvic MRI. Surgical procedures followed ESMO guidelines, with histopathological assessments using FIGO 2009 criteria. Two radiologists independently evaluated MRI images, measuring maximum tumor size, minimum tumor ADC value (using a free-hand ROI technique), and ADC tumor/myometrium ratio. MRI findings were compared with histopathological data.
RESULTS: Peritoneal implant presence and tumor size exhibited significant differences between endometrioid adenocarcinoma (EAC) and non-endometrioid endometrial carcinoma (NEEC), with p values of < 0.001 and 0.003, respectively. Significant differences in age, tumor size, ADC tumor, and ADC tumor/myometrium between low-grade and high-grade tumors were observed, with p values of < 0.001, 0.004, 0.006, and 0.011, respectively. Increased tumor size, reduced ADC tumor, ADC tumor/myometrium, and pelvic peritoneal implant presence were significantly associated with LVSI, with p values of < 0.001, 0.001, 0.002, and 0.001, respectively. The AUC values for tumor size, ADC tumor, and ADC tumor/myometrium were 0.842, 0.781 and 0.747, respectively, in distinguishing between low and high-grade endometrial tumors. Similarly, obtained AUC values for predicting LVSI were 0.836, 0.719, and 0.696, respectively.
CONCLUSION: Our study emphasizes MRI's role in predicting tumor characteristics such as histological subtype, grade, and LVSI based on updated FIGO criteria. By highlighting the potential of MRI, this research contributes to our comprehension of improving diagnostic and clinical management for EC. Further multicenter studies are warranted to validate these findings and establish MRI's role in EC management.
引用
- Akçay A, Gültekin MA, Altıntaş F, et al. Updated endometrial cancer FIGO staging: the role of MRI in determining newly included histopathological criteria. Abdom Radiol (NY). 2024. PMID: 38836884. doi:10.1007/s00261-024-04398-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。